Trials / NCT04925687
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Completed Phase 1 Cell therapy
- Sponsor
- University of California, Davis
- Treatment
- Intravitreal autologous CD34+ cells
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 4 participants
- Started
- 2021-06-01
- Main results expected
- 2023-11-01
- Results posted
- Not yet
- Record last updated
- 2024-09-23
What the study is testing
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.
Where it runs
United States (1)
- University of California Davis, Sacramento, California